https://scholars.lib.ntu.edu.tw/handle/123456789/636694
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Merle, Philippe | en_US |
dc.contributor.author | Kudo, Masatoshi | en_US |
dc.contributor.author | Edeline, Julien | en_US |
dc.contributor.author | Bouattour, Mohamed | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.contributor.author | Chan, Stephen L | en_US |
dc.contributor.author | Yau, Thomas | en_US |
dc.contributor.author | Garrido, Marcelo | en_US |
dc.contributor.author | Knox, Jennifer | en_US |
dc.contributor.author | Daniele, Bruno | en_US |
dc.contributor.author | Breder, Valeriy | en_US |
dc.contributor.author | Lim, Ho Yeong | en_US |
dc.contributor.author | Ogasawara, Sadahisa | en_US |
dc.contributor.author | Cattan, Stéphane | en_US |
dc.contributor.author | Chao, Yee | en_US |
dc.contributor.author | Siegel, Abby B | en_US |
dc.contributor.author | Martinez-Forero, Iván | en_US |
dc.contributor.author | Wei, Ziwen | en_US |
dc.contributor.author | Liu, Chih-Chin | en_US |
dc.contributor.author | Finn, Richard S | en_US |
dc.date.accessioned | 2023-10-31T03:10:55Z | - |
dc.date.available | 2023-10-31T03:10:55Z | - |
dc.date.issued | 2023-09 | - |
dc.identifier.issn | 2235-1795 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/636694 | - |
dc.description.abstract | KEYNOTE-240 showed a favorable benefit/risk profile for pembrolizumab versus placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC); however, prespecified statistical significance criteria for overall survival (OS) and progression-free survival (PFS) superiority were not met at the final analysis. Outcomes based on an additional 18 months of follow-up are reported. | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Liver cancer | en_US |
dc.subject | Hepatocellular carcinoma; Long-term follow-up; Pembrolizumab; Programmed cell death protein 1 | en_US |
dc.title | Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1159/000529636 | - |
dc.identifier.pmid | 37901200 | - |
dc.identifier.scopus | 2-s2.0-85163701825 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85163701825 | - |
dc.relation.journalvolume | 12 | en_US |
dc.relation.journalissue | 4 | en_US |
dc.relation.pageend | 320 | en_US |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。